IRIS UniCatt

Rossi, Elena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.502
EU - Europa 2.366
AS - Asia 1.065
SA - Sud America 325
AF - Africa 47
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.319
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.462
DE - Germania 690
SE - Svezia 433
IT - Italia 392
SG - Singapore 383
CN - Cina 349
BR - Brasile 290
FR - Francia 165
UA - Ucraina 142
IE - Irlanda 124
PL - Polonia 105
GB - Regno Unito 93
ID - Indonesia 76
IN - India 75
RU - Federazione Russa 57
FI - Finlandia 54
AT - Austria 29
VN - Vietnam 27
CA - Canada 20
KR - Corea 20
IQ - Iraq 18
HK - Hong Kong 16
BE - Belgio 15
CI - Costa d'Avorio 15
BD - Bangladesh 14
NL - Olanda 13
TR - Turchia 13
AR - Argentina 12
MX - Messico 12
ES - Italia 10
IR - Iran 10
AU - Australia 9
SA - Arabia Saudita 9
PK - Pakistan 8
ZA - Sudafrica 8
JP - Giappone 7
LT - Lituania 7
CH - Svizzera 6
MA - Marocco 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
DZ - Algeria 4
EC - Ecuador 4
LV - Lettonia 4
PE - Perù 4
RO - Romania 4
TN - Tunisia 4
UY - Uruguay 4
VE - Venezuela 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
CZ - Repubblica Ceca 3
EE - Estonia 3
EG - Egitto 3
JM - Giamaica 3
KE - Kenya 3
MY - Malesia 3
TH - Thailandia 3
DK - Danimarca 2
GA - Gabon 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
TW - Taiwan 2
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EU - Europa 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
JO - Giordania 1
KH - Cambogia 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
Totale 6.319
Salva come PNG Salva come JPEG
Città #
Chandler 485
Singapore 230
Ashburn 222
Dublin 119
Wilmington 94
San Mateo 86
Jacksonville 85
Rome 82
Fairfield 80
Warsaw 76
Munich 75
Jakarta 73
Milan 67
Ann Arbor 66
Cattolica 61
Dearborn 61
Nanjing 61
New York 60
Houston 58
Boston 56
Woodbridge 56
Los Angeles 40
Marseille 39
Seattle 39
Moscow 38
Princeton 38
Hefei 35
Hyderabad 33
Redwood City 32
Chicago 28
Frankfurt am Main 26
Lawrence 26
Nürnberg 25
São Paulo 25
Beijing 24
Detroit 23
Kraków 23
Redmond 23
Nanchang 22
Cambridge 20
Bologna 18
Hangzhou 18
Nuremberg 18
Hebei 17
Seoul 17
Hong Kong 16
Abidjan 15
Boardman 15
Brussels 15
Washington 15
Helsinki 14
Leawood 14
Norwalk 14
Vienna 14
London 12
Belo Horizonte 11
Changsha 10
Düsseldorf 10
Florence 10
Hanoi 10
The Dalles 10
Tianjin 10
Toronto 10
Bremen 9
Mountain View 9
Paris 9
San Diego 9
Bexley 8
Pune 8
Turku 8
Guangzhou 7
Kunming 7
Portsmouth 7
Rio de Janeiro 7
University Park 7
Busto Arsizio 6
Lancaster 6
Santa Clara 6
Shenyang 6
Tashkent 6
Wroclaw 6
Atlanta 5
Baghdad 5
Baku 5
Brooklyn 5
Buenos Aires 5
Campinas 5
Dhaka 5
Izmir 5
Jiaxing 5
Madrid 5
Ottawa 5
Perugia 5
Reston 5
Salvador 5
Shanghai 5
Simi Valley 5
Zhengzhou 5
Andover 4
Brasília 4
Totale 3.349
Salva come PNG Salva come JPEG
Nome #
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization 284
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. 275
Haemostatic alterations induced by treatment with asparaginases and clinical consequences 208
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis 187
Risk factor and etiology analysis of ischemic stroke in young adult patients 156
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 143
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 143
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment 135
Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms : Long-Term Experience. 134
Fondaparinux in pregnancy: Could it be a safe option? A review of the literature. 128
Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms 123
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments 122
Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia 116
Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms 113
Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms 111
Venous thromboembolism in multiple myeloma 111
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls 108
JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis 106
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 103
The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia 97
Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation 97
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 95
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment 93
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 92
Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities 91
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 89
Inherited thrombophilia: treatment during pregnancy. 88
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists 84
Assessment of congenital neutropenia in children: common clinical sceneries and clues for management 84
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 82
Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation 81
In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband 81
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 81
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 79
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 77
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 74
Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups 73
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 73
Isolated light chain deposition disease neuropathy in a patient with multiple myeloma 71
Structural analysis of protein Z gene variants in patients with foetal losses 67
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 67
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years 65
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 64
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population 64
Cerebral sinus-venous thrombosis 62
Venous thromboembolism in patients with liver diseases 60
Predicting Factors for Seizures after Cerebral Venous Thrombosis: A Retrospective Single Center Cohort Study 59
Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia 59
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 58
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 57
Venous thromboembolism in patients with liver diseases 56
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study 56
Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis? 55
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 55
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls 53
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 53
Contractile reserve of dysfunctional myocardium after revascularization: A dobutamine stress echocardiography study 53
Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease 53
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 52
Glycoprotein la C807T qene polymorphism and increased risk of recurrent acute coronary syndromes: A five year follow up 51
Second cancers in MPN: Survival analysis from an international study 49
Reassessment of contractile reserve after revascularization of akinetic myocardium 49
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 48
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 48
Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms 46
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus 45
Predicting Factors for Seizures after Cerebral Venous Thrombosis: A Retrospective Single Center Cohort Study 39
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases 36
G20210A protrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 35
Methylation Analysis of Urinary Sample in Non-Muscle-Invasive Bladder Carcinoma: Frequency and Management of Invalid Result 34
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 33
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 32
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial 30
Coagulopathy in CAR-T: Critical concern or mere blip? 30
Glycoprotein IA C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up. 28
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 27
Risk factor and etiology analysis of ischemic stroke in young adult patients 26
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 26
Left atrial myxoma supplied from the right coronary artery 25
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 19
ROLE OF 18 F-FDG PET/CT IN THE ASSESSMENT OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA 19
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 19
Totale 6.450
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.159
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.159
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021478 26 43 20 56 49 37 53 22 56 26 76 14
2021/2022668 46 35 16 40 32 13 20 80 45 45 121 175
2022/20231.356 203 197 115 199 77 159 79 84 154 25 35 29
2023/2024742 28 177 30 52 34 127 37 40 14 31 80 92
2024/20251.552 26 67 91 62 121 37 59 71 254 165 325 274
2025/2026166 166 0 0 0 0 0 0 0 0 0 0 0
Totale 6.450